• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[地拉氟沙星对阿根廷布宜诺斯艾利斯骨关节炎和皮肤感染分离菌株的体外活性]

[In vitro activity of delafloxacin against bacterial isolates from osteoarticular and skin infections in Buenos Aires, Argentina].

作者信息

Nicola Federico, Azula Natalia, Santoni Gabriela, Smayevsky Jorgelina

机构信息

Laboratorio de Bacteriología, Micología y Parasitología; Departamento de Análisis Clínicos; Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Av. Galván 4102, Ciudad Autónoma de Buenos Aires, Argentina.

Laboratorio de Bacteriología, Micología y Parasitología; Departamento de Análisis Clínicos; Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Av. Galván 4102, Ciudad Autónoma de Buenos Aires, Argentina.

出版信息

Rev Argent Microbiol. 2022 Apr-Jun;54(2):114-119. doi: 10.1016/j.ram.2021.02.012. Epub 2021 May 28.

DOI:10.1016/j.ram.2021.02.012
PMID:34053809
Abstract

In vitro activities of delafloxacin, ciprofloxacin and levofloxacin were evaluated by epsilometric and disk diffusion methods against 181 bacterial isolates recovered from bone and skin infections. Isolates included were 84 Staphylococcus aureus (40 MRSA and 44 MSSA), 46 coagulase-negative staphylococci (CNS), 23 Klebsiella pneumoniae and 28 Pseudomonas aeruginosa. The MIC/MIC (mg/l) for delafloxacin, ciprofloxacin and levofloxacin, respectively, were: MRSA, 0.004/0.064, 0.25/16 and 0.125/4; MSSA, 0.002/0.004, 0.125/0.25 and 0.125/0.25; CNS, 0.008/0.25, 0.125/>32 and 0.25/>32; K. pneumoniae, 4/>32,>32/>32 and 16/>32; P. aeruginosa, 1/>32, 0,5/>32 and 4/>32. Susceptibilities for delafloxacin, ciprofloxacin and levofloxacin, respectively, were: MRSA, 97.5%, 82.5% and 82.5%; MSSA, 97.7%, 95.5% and 95.5%; CNS, 93.5%, 63.0% and 60.9%; K. pneumoniae, 21.7%, 26.1% and 43.5%; P aeruginosa, 35.7%, 53.6% and 42.8%. The disk diffusion and epsilometric methods were concordant for evaluating in vitro susceptibility in staphylococci (categorical concordance of 98.8% for S. aureus and 91.3% for CNS).

摘要

采用比浊法和纸片扩散法,对从骨感染和皮肤感染中分离出的181株细菌,评估了德拉氟沙星、环丙沙星和左氧氟沙星的体外活性。分离出的细菌包括84株金黄色葡萄球菌(40株耐甲氧西林金黄色葡萄球菌和44株甲氧西林敏感金黄色葡萄球菌)、46株凝固酶阴性葡萄球菌(CNS)、23株肺炎克雷伯菌和28株铜绿假单胞菌。德拉氟沙星、环丙沙星和左氧氟沙星的MIC/MIC(mg/l)分别为:耐甲氧西林金黄色葡萄球菌,0.004/0.064、0.25/16和0.125/4;甲氧西林敏感金黄色葡萄球菌,0.002/0.004、0.125/0.25和0.125/0.25;凝固酶阴性葡萄球菌,0.008/0.25、0.125/>32和0.25/>32;肺炎克雷伯菌,4/>32、>32/>32和16/>32;铜绿假单胞菌,1/>32、0.5/>32和4/>32。德拉氟沙星、环丙沙星和左氧氟沙星的敏感性分别为:耐甲氧西林金黄色葡萄球菌,97.5%、82.5%和82.5%;甲氧西林敏感金黄色葡萄球菌,97.7%、95.5%和95.5%;凝固酶阴性葡萄球菌,93.5%、63.0%和60.9%;肺炎克雷伯菌,21.7%、26.1%和43.5%;铜绿假单胞菌,35.7%、53.6%和42.8%。纸片扩散法和比浊法在评估葡萄球菌的体外敏感性方面具有一致性(金黄色葡萄球菌的分类一致性为98.8%,凝固酶阴性葡萄球菌为91.3%)。

相似文献

1
[In vitro activity of delafloxacin against bacterial isolates from osteoarticular and skin infections in Buenos Aires, Argentina].[地拉氟沙星对阿根廷布宜诺斯艾利斯骨关节炎和皮肤感染分离菌株的体外活性]
Rev Argent Microbiol. 2022 Apr-Jun;54(2):114-119. doi: 10.1016/j.ram.2021.02.012. Epub 2021 May 28.
2
Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections.两项急性细菌性皮肤和皮肤结构感染 3 期研究中分离的氟喹诺酮敏感和不敏感金黄色葡萄球菌分离株的达托霉素活性和微生物学应答。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00772-17. Print 2017 Sep.
3
Comparative in vitro activity of Delafloxacin and other antimicrobials against isolates from patients with acute bacterial skin, skin-structure infection and osteomyelitis.德拉氟沙星与其他抗菌药物对急性细菌性皮肤、皮肤结构感染和骨髓炎患者分离菌株的体外活性比较
Braz J Infect Dis. 2024 Nov-Dec;28(6):103867. doi: 10.1016/j.bjid.2024.103867. Epub 2024 Sep 18.
4
Delafloxacin--A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis.德拉沙星——一种治疗囊性纤维化患者对环丙沙星耐药铜绿假单胞菌的新型氟喹诺酮类药物。
Clin Respir J. 2021 Jan;15(1):116-120. doi: 10.1111/crj.13262. Epub 2020 Sep 7.
5
In vitro activity of delafloxacin against highly levofloxacin-resistant invasive isolates of Streptococcus pneumoniae.体外研究达氟沙星对高度左氧氟沙星耐药的侵袭性肺炎链球菌分离株的活性。
Enferm Infecc Microbiol Clin (Engl Ed). 2022 Mar;40(3):131-133. doi: 10.1016/j.eimce.2020.09.009.
6
Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014.2014年达氟沙星对来自美国和欧洲的当代细菌病原体的活性
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02609-16. Print 2017 Apr.
7
Delafloxacin activity against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid.达托霉素、利奈唑胺、万古霉素或甲氧西林中介或耐药金黄色葡萄球菌的达氟沙星活性。
J Antimicrob Chemother. 2020 Sep 1;75(9):2605-2608. doi: 10.1093/jac/dkaa209.
8
Efficacy of delafloxacin alone and in combination with cefotaxime against cefotaxime non-susceptible invasive isolates of Streptococcus pneumoniae.单独使用和联合使用头孢噻肟治疗头孢噻肟不敏感的侵袭性肺炎链球菌分离株的疗效。
Rev Esp Quimioter. 2024 Apr;37(2):158-162. doi: 10.37201/req/107.2023. Epub 2024 Jan 16.
9
Comparison of the in vitro activities of delafloxacin and comparators against Staphylococcus epidermidis clinical strains involved in osteoarticular infections: a CRIOGO multicentre retrospective study.地拉氟沙星与对照药物对参与骨关节炎感染的表皮葡萄球菌临床菌株的体外活性比较:一项CRIOGO多中心回顾性研究。
J Antimicrob Chemother. 2024 May 2;79(5):1045-1050. doi: 10.1093/jac/dkae071.
10
High-level delafloxacin resistance through the combination of two different mechanisms in Staphylococcus aureus.金黄色葡萄球菌中两种不同机制共同导致高水平达托霉素耐药性。
Int J Antimicrob Agents. 2023 Jun;61(6):106795. doi: 10.1016/j.ijantimicag.2023.106795. Epub 2023 Mar 24.

引用本文的文献

1
Comparative in vitro activity of Delafloxacin and other antimicrobials against isolates from patients with acute bacterial skin, skin-structure infection and osteomyelitis.德拉氟沙星与其他抗菌药物对急性细菌性皮肤、皮肤结构感染和骨髓炎患者分离菌株的体外活性比较
Braz J Infect Dis. 2024 Nov-Dec;28(6):103867. doi: 10.1016/j.bjid.2024.103867. Epub 2024 Sep 18.